Adamis Pharmaceuticals Corp (NASDAQ:ADMP)’s share price was up 5.8% during mid-day trading on Wednesday . The company traded as high as $4.60 and last traded at $4.55. Approximately 624,032 shares were traded during mid-day trading, a decline of 15% from the average daily volume of 731,335 shares. The stock had previously closed at $4.30.

A number of equities analysts have issued reports on ADMP shares. Raymond James Financial started coverage on Adamis Pharmaceuticals in a report on Tuesday, September 12th. They issued an “outperform” rating and a $7.00 price objective for the company. ValuEngine downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. B. Riley reiterated a “buy” rating and issued a $9.50 price objective on shares of Adamis Pharmaceuticals in a report on Wednesday, October 4th. Zacks Investment Research downgraded Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 20th. Finally, Maxim Group set a $14.00 price objective on Adamis Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 5th. Two analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. Adamis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $10.33.

The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06.

A number of institutional investors and hedge funds have recently bought and sold shares of ADMP. First Allied Advisory Services Inc. bought a new position in Adamis Pharmaceuticals in the second quarter worth $114,000. Stonebridge Capital Advisors LLC raised its holdings in Adamis Pharmaceuticals by 22.2% in the second quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock worth $143,000 after purchasing an additional 5,000 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Adamis Pharmaceuticals by 131.0% in the third quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock worth $143,000 after acquiring an additional 15,577 shares during the last quarter. Wells Fargo & Company MN purchased a new stake in shares of Adamis Pharmaceuticals in the second quarter worth $169,000. Finally, IFP Advisors Inc grew its stake in shares of Adamis Pharmaceuticals by 2,245.6% in the second quarter. IFP Advisors Inc now owns 34,433 shares of the specialty pharmaceutical company’s stock worth $179,000 after acquiring an additional 32,965 shares during the last quarter. Institutional investors and hedge funds own 16.61% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Adamis Pharmaceuticals (ADMP) Trading Up 5.8%” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/21/adamis-pharmaceuticals-admp-trading-up-5-8.html.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Receive News & Stock Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related stocks with our FREE daily email newsletter.